Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 82

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Polygenic architecture informs potential vulnerability to drug-induced liver injury

Koido, Masaru, Kawakami, Eri, Fukumura, Junko, Noguchi, Yui, Ohori, Momoko, Nio, Yasunori, Nicoletti, Paola, Aithal, Guruprasad P., Daly, Ann K., Watkins, Paul B., Anayama, Hisashi, Dragan, Yvonne, Shinozawa, Tadahiro, Takebe, Takanori · 2020 · Nature Medicine

Abstract

Drug-induced liver injury (DILI) is a leading cause of termination in drug development programs and removal of drugs from the market; this is partially due to the inability to identify patients who are at risk1. In this study, we developed a polygenic risk score (PRS) for DILI by aggregating effects of numerous genome-wide loci identified from previous large-scale genome-wide association studies2. The PRS predicted the susceptibility to DILI in patients treated with fasiglifam, amoxicillin–clavulanate or flucloxacillin and in primary hepatocytes and stem cell-derived organoids from multiple donors treated with over ten different drugs. Pathway analysis highlighted processes previously implicated in DILI, including unfolded protein responses and oxidative stress. In silico screening identified compounds that elicit transcriptomic signatures present in hepatocytes from individuals with elevated PRS, supporting mechanistic links and suggesting a novel screen for safety of new drug candidates. This genetic-, cellular-, organoid- and human-scale evidence underscored the polygenic architecture underlying DILI vulnerability at the level of hepatocytes, thus facilitating future mechanistic studies. Moreover, the proposed ‘polygenicity-in-a-dish’ strategy might potentially inform designs of safer, more efficient and robust clinical trials. Polygenic risk scores can predict susceptibility to drug-induced liver injury in patients and can stratify cellular viability of iPSC-derived liver organoids and primary hepatocytes from multiple donors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-020-1023-0

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 31

  1. Chalasani, N. et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology 148, 1340–1352 (2015). · DOI · Paper page
  2. Nicoletti, P. et al. Association of liver injury from specific drugs, or groups of drugs, with polymorphisms in HLA and other genes in a genome-wide association study. Gastroenterology 152, 1078–1089 (2017). · DOI · Paper page
  3. Marcinak, J. F., Munsaka, M. S., Watkins, P. B., Ohira, T. & Smith, N. Liver safety of fasiglifam (TAK-875) in patients with type 2 diabetes: review of the global clinical trial experience. Drug Saf. 41, 625–640 (2018). · DOI
  4. Wolenski, F. S. et al. Fasiglifam (TAK-875) alters bile acid homeostasis in rats and dogs: a potential cause of drug induced liver injury. Toxicol. Sci. 157, 50–61 (2017).
  5. McCall, M. N., Bolstad, B. M. & Irizarry, R. A. Frozen robust multiarray analysis (fRMA). Biostatistics 11, 242–253 (2010). · DOI · Paper page
  6. Iotchkova, V. et al. GARFIELD classifies disease-relevant genomic features through integration of functional annotations with association signals. Nat. Genet. 51, 343–353 (2019). · DOI · Paper page
  7. Lamparter, D., Marbach, D., Rueedi, R., Kutalik, Z. & Bergmann, S. Fast and rigorous computation of gene and pathway scores from SNP-based summary statistics. PLoS Comput. Biol. 12, 1–20 (2016). · DOI · Paper page
  8. Kass, G. E. N. & Price, S. C. Role of mitochondria in drug-induced cholestatic injury. Clin. Liver Dis. 12, 27–51 (2008). · DOI
  9. Vatakuti, S., Olinga, P., Pennings, J. L. A. & Groothuis, G. M. M. Validation of precision-cut liver slices to study drug-induced cholestasis: a transcriptomics approach. Arch. Toxicol. 91, 1401–1412 (2017). · DOI
  10. Cirulli, E. T. et al. A missense variant in PTPN22 is a risk factor for drug-induced liver injury. Gastroenterology 156, 1707–1716 (2019). · DOI · Paper page
  11. Takebe, T. et al. Massive and reproducible production of liver buds entirely from human pluripotent stem cells. Cell Rep. 21, 2661–2670 (2017). · DOI · Paper page
  12. Ogimura, E., Sekine, S. & Horie, T. Bile salt export pump inhibitors are associated with bile acid-dependent drug-induced toxicity in sandwich-cultured hepatocytes. Biochem. Biophys. Res. Commun. 416, 313–317 (2011). · DOI
  13. Delaneau, O. et al. Chromatin three-dimensional interactions mediate genetic effects on gene expression. Science 364, eaat8266 (2019). · DOI · Paper page
  14. Schadt, E. E. et al. Mapping the genetic architecture of gene expression in human liver. PLoS Biol. 6, 1020–1032 (2008). · DOI · Paper page
  15. Hybertson, B. M., Gao, B., Bose, S. K. & McCord, J. M. Oxidative stress in health and disease: the therapeutic potential of Nrf2 activation. Mol. Asp. Med. 32, 234–246 (2011). · DOI · Paper page
  16. Igarashi, Y. et al. Open TG-GATEs: a large-scale toxicogenomics database. Nucleic Acids Res. 43, D921–D927 (2015). · DOI · Paper page
  17. Kaliyaperumal, K. et al. Pharmacogenomics of drug-induced liver injury (DILI): molecular biology to clinical applications. J. Hepatol. 69, 948–957 (2018). · DOI
  18. Chen, M. et al. Drug-induced liver injury: interactions between drug properties and host factors. J. Hepatol. 63, 503–514 (2015). · DOI · Paper page
  19. Daly, A. K. et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat. Genet. 41, 816–819 (2009). · DOI · Paper page
  20. Lucena, M. I. et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 141, 338–347 (2011). · DOI · Paper page
  21. Fredriksson, L. et al. Drug-induced endoplasmic reticulum and oxidative stress responses independently sensitize toward TNFα-mediated hepatotoxicity. Toxicol. Sci. 140, 144–159 (2014). · DOI
  22. Burban, A., Sharanek, A., Guguen-Guillouzo, C. & Guillouzo, A. Endoplasmic reticulum stress precedes oxidative stress in antibiotic-induced cholestasis and cytotoxicity in human hepatocytes. Free Radic. Biol. Med. 115, 166–178 (2018). · DOI
  23. Fabregat, A. et al. The reactome pathway knowledgebase. Nucleic Acids Res. 46, D649–D655 (2018). · DOI · Paper page
  24. Gibbs, R. A. et al. A global reference for human genetic variation. Nature 526, 68–74 (2015). · DOI · Paper page
  25. Loh, P.-R. et al. Reference-based phasing using the haplotype reference consortium panel. Nat. Genet. 48, 1443–1448 (2016). · DOI · Paper page
  26. Marchini, J. & Howie, B. Genotype imputation for genome-wide association studies. Nat. Rev. Genet. 11, 499–511 (2010). · DOI · Paper page
  27. Euesden, J., Lewis, C. M. & O’Reilly, P. F. PRSice: polygenic risk score software. Bioinformatics 31, 1466–1468 (2015). · DOI · Paper page
  28. Asai, A. et al. Paracrine signals regulate human liver organoid maturation from induced pluripotent stem cells. Development 144, 1056–1064 (2017). · DOI
  29. Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013). · DOI · Paper page
  30. Lo, C.-C. & Chain, P. S. G. Rapid evaluation and quality control of next generation sequencing data with FaQCs. BMC Bioinf. 15, 366 (2014). · DOI · Paper page
  31. Trapnell, C. et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat. Biotechnol. 28, 511–515 (2010). · DOI · Paper page

Cited by

See all 82

Metadata

Authors
Koido, M., Kawakami, E., Fukumura, J., Noguchi, Y., Ohori, M., Nio, Y., Nicoletti, P., Aithal, G. P., Daly, A. K., Watkins, P. B., Anayama, H., Dragan, Y., Shinozawa, T., & Takebe, T.
Venue
Nature Medicine
Published
2020-09-07
Volume
26
Issue
10
Pages
1541-1548
ISSN
  • 1078-8956
  • 1546-170X
Cited by
82
References
9
Language
en
Licence
Funders
  • Takeda Pharmaceutical Company (T-CiRA program)
  • RCUK | Medical Research Council (MC_PC_17173)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Polygenic architecture informs potential vulnerability to drug-induced liver injury. https://app.cochat.ai/papers/10.1038/s41591-020-1023-0
The paper
Koido, M., Kawakami, E., Fukumura, J., Noguchi, Y., Ohori, M., Nio, Y., Nicoletti, P., Aithal, G. P., Daly, A. K., Watkins, P. B., Anayama, H., Dragan, Y., Shinozawa, T., & Takebe, T. (2020). Polygenic architecture informs potential vulnerability to drug-induced liver injury. Nature Medicine. https://doi.org/10.1038/s41591-020-1023-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.